Crispr Therapeutics (CRSP) Superinvestor holders
10 of the superinvestors we track hold Crispr Therapeutics (CRSP) in their latest 13F filings, $686M in total.
Summary
The largest holder is Cathie Wood (ARK Investment Management), with $516M, 3.4% of the portfolio.
In their latest quarter: 1 opened a new position, 3 added, 6 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Cathie Wood ARK Investment Management |
Trimmed | 9,460,939 | $516M | 3.4% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Added | 1,988,621 | $108M | 0.1% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
New position | 893,812 | $49M | 0.0% | Q2 2026 |
| Man Group Man Group plc |
Trimmed | 73,194 | $4M | 0.0% | Q2 2026 |
| Ken Fisher Fisher Investments |
Trimmed | 67,302 | $4M | 0.0% | Q3 2026 |
| Paul Tudor Jones Tudor Investment Corp |
Trimmed | 42,512 | $2M | 0.0% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | 28,597 | $2M | 0.0% | Q2 2026 |
| Alan Howard Brevan Howard |
Added | 12,459 | $679,514 | 0.0% | Q2 2026 |
| Murray Stahl Horizon Kinetics LLC |
Trimmed | 9,353 | $510,113 | 0.0% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
Trimmed | 4,664 | $254,375 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 10 |
| Q1 2026 | 9 |
| Q4 2025 | 8 |
| Q3 2025 | 7 |
| Q2 2025 | 8 |
| Q1 2025 | 8 |
| Q4 2024 | 8 |
| Q3 2024 | 11 |
Questions about Crispr Therapeutics
Which superinvestors own Crispr Therapeutics?
10 of the superinvestors we track hold Crispr Therapeutics (CRSP) in their latest 13F filings, $686M in total. Cathie Wood, Two Sigma, David Shaw, Man Group, Ken Fisher, Paul Tudor Jones.
Who is the largest superinvestor holder of CRSP?
The largest holder is Cathie Wood (ARK Investment Management), with $516M, 3.4% of the portfolio.
From Crispr Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.